Randomized phase II study (EORTC 08062) of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED SCLC).

M. O'Brien; J. Jassem; P. Lorigan; L. Bosquée; E. Marshall; F. Bustin; J. Stigt; A. C. Dingemans; B. Hasan; J. P. Van Meerbeeck

doi:10.1200/jco.2010.28.15_suppl.7052

Randomized phase II study (EORTC 08062) of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED SCLC).

M. O'Brien, J. Jassem, P. Lorigan, L. Bosquée, E. Marshall, F. Bustin, J. Stigt, A. C. Dingemans, B. Hasan, J. P. Van Meerbeeck

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	7052-7052
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	28
Issue number	15_suppl
DOIs	https://doi.org/10.1200/jco.2010.28.15_suppl.7052
Publication status	Published - 24 Feb 2017

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/jco.2010.28.15_suppl.7052

Cite this

O'Brien, M., Jassem, J., Lorigan, P., Bosquée, L., Marshall, E., Bustin, F., Stigt, J., Dingemans, A. C., Hasan, B., & Van Meerbeeck, J. P. (2017). Randomized phase II study (EORTC 08062) of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED SCLC). Journal of Clinical Oncology, 28(15_suppl), 7052-7052. https://doi.org/10.1200/jco.2010.28.15_suppl.7052

@article{2f5e645471044987b556f6d705c2d1b7,

title = "Randomized phase II study (EORTC 08062) of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED SCLC).",

author = "M. O'Brien and J. Jassem and P. Lorigan and L. Bosqu{\'e}e and E. Marshall and F. Bustin and J. Stigt and Dingemans, {A. C.} and B. Hasan and {Van Meerbeeck}, {J. P.}",

year = "2017",

month = feb,

day = "24",

doi = "10.1200/jco.2010.28.15_suppl.7052",

language = "English",

volume = "28",

pages = "7052--7052",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams & Wilkins",

number = "15_suppl",

}

O'Brien, M, Jassem, J, Lorigan, P, Bosquée, L, Marshall, E, Bustin, F, Stigt, J, Dingemans, AC, Hasan, B & Van Meerbeeck, JP 2017, 'Randomized phase II study (EORTC 08062) of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED SCLC).', Journal of Clinical Oncology, vol. 28, no. 15_suppl, pp. 7052-7052. https://doi.org/10.1200/jco.2010.28.15_suppl.7052

Randomized phase II study (EORTC 08062) of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED SCLC). / O'Brien, M.; Jassem, J.; Lorigan, P. et al.
In: Journal of Clinical Oncology, Vol. 28, No. 15_suppl, 24.02.2017, p. 7052-7052.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Randomized phase II study (EORTC 08062) of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED SCLC).

AU - O'Brien, M.

AU - Jassem, J.

AU - Lorigan, P.

AU - Bosquée, L.

AU - Marshall, E.

AU - Bustin, F.

AU - Stigt, J.

AU - Dingemans, A. C.

AU - Hasan, B.

AU - Van Meerbeeck, J. P.

PY - 2017/2/24

Y1 - 2017/2/24

U2 - 10.1200/jco.2010.28.15_suppl.7052

DO - 10.1200/jco.2010.28.15_suppl.7052

M3 - Article

SN - 0732-183X

VL - 28

SP - 7052

EP - 7052

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 15_suppl

ER -

O'Brien M, Jassem J, Lorigan P, Bosquée L, Marshall E, Bustin F et al. Randomized phase II study (EORTC 08062) of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED SCLC). Journal of Clinical Oncology. 2017 Feb 24;28(15_suppl):7052-7052. doi: 10.1200/jco.2010.28.15_suppl.7052